The World Health Organization's End TB Strategy prioritizes universal access to an early
diagnosis and comprehensive drug susceptibility testing (DST) for all individuals with …

Background Outcomes of treatment of tuberculosis patients with regimens including
pretomanid have not yet been systematically reviewed. Objectives To appraise existing …

To be effective, chemotherapy against tuberculosis (TB) must kill the intracellular population
of the pathogen, Mycobacterium tuberculosis. However, how host cell microenvironments …

Tuberculosis (TB) is the most deadly infectious disease globally. Although most individuals
achieve a cure, a substantial portion develop multi-drug resistant TB which is exceedingly …

This article provides an encompassing review of the current pipeline of putative and
developed treatments for tuberculosis, including multidrug-resistant strains. The review has …

The clinical development and regulatory approval of bedaquiline, delamanid and
pretomanid over the last decade brought about significant progress in the management of …

Multidrug-resistant (MDR) tuberculosis (TB), resistant to isoniazid and rifampicin, continues
to be one of the most important threats to controlling the TB epidemic. Over the last few …

Eighty years after the introduction of the first antituberculosis (TB) drug, the treatment of drug-
susceptible TB remains very cumbersome, requiring the use of four drugs (isoniazid …

Bedaquiline (B), pretomanid (Pa) and linezolid (L) are key components of new regimens for
treating rifampicin-resistant tuberculosis (TB). However, there is limited information on the …

Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6
months), poor patient adherence, high inter-individual variability in pharmacokinetics (PK) …